TC, Ariad's advantage in the New molecule clinical trials once announced will be that it will be fitted against placebos only because there is no current treatment for an unmet medical need indication that ariad may be targetting. Even a slight or mediocre advantage in the trials over placebos maybe considered successful, just speculating. So, once P1 and P2 are over and successful, accelerated approval may follow. Unlike 113 and pona(CML), they have to go against existing therapies and it cost ariad extra money to conclude the trials. Trials for Nmole will not be as expensive as 113 or pona(cml)...jmo.
